Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (öffnet neues Fenster)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Quelle‎: Cancer 2013;119(21):3784-7.

Indiziert‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (öffnet neues Fenster)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (öffnet neues Fenster)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Quelle‎: Lancet 1989;334(8655):122-4.

Indiziert‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (öffnet neues Fenster)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (öffnet neues Fenster)

Ben-Bassat I, Douer D, Ramot B.

Quelle‎: Eur J Haematol 1990;45(2):86-9.

Indiziert‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (öffnet neues Fenster)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (öffnet neues Fenster)

Dean A, Tuffin P.

Quelle‎: J Pain Symptom Manage 1997;13(1):20-4.

Indiziert‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (öffnet neues Fenster)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (öffnet neues Fenster)

Ford PA, Grant SJ, Mick R, Keck G.

Quelle‎: J Clin Oncol 2015;33(15):1674-9.

Indiziert‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (öffnet neues Fenster)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (öffnet neues Fenster)

Garewal HS, Durie BG.

Quelle‎: Scand J Haematol 1985;35(5):497-500.

Indiziert‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (öffnet neues Fenster)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (öffnet neues Fenster)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Quelle‎: Cancer 2006;107(1):136-40.

Indiziert‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (öffnet neues Fenster)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (öffnet neues Fenster)

Marshall A, Li A, Drucker A, Dzik W.

Quelle‎: Hematol Oncol 2016;34(3):147-53.

Indiziert‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (öffnet neues Fenster)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (öffnet neues Fenster)

Prokopchuk-Gauk O, Brose K.

Quelle‎: Cureus 2015;7(12):e428.

Indiziert‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (öffnet neues Fenster)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (öffnet neues Fenster)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Quelle‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indiziert‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (öffnet neues Fenster)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (öffnet neues Fenster)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Quelle‎: Hematol Oncol 2008;26(4):241-6.

Indiziert‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (öffnet neues Fenster)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (öffnet neues Fenster)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Quelle‎: Am J Hematol 2006;81(9):720.

Indiziert‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (öffnet neues Fenster)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (öffnet neues Fenster)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Quelle‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indiziert‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (öffnet neues Fenster)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (öffnet neues Fenster)

Erduran E, Bahadir A, Mutlu M.

Quelle‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Indiziert‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (öffnet neues Fenster)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (öffnet neues Fenster)

Franchini M, Veneri D, Lippi G.

Quelle‎: Bone Marrow Transplant 2007;39(12):729-35.

Indiziert‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (öffnet neues Fenster)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (öffnet neues Fenster)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Quelle‎: Am J Hematol 2002;69(3):219-22.

Indiziert‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (öffnet neues Fenster)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (öffnet neues Fenster)

Hsieh A, Cheong I.

Quelle‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Indiziert‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (öffnet neues Fenster)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (öffnet neues Fenster)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Quelle‎: Haemostasis 1996;26 Suppl 1:159-64.

Indiziert‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (öffnet neues Fenster)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (öffnet neues Fenster)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Quelle‎: Med Oncol 2010;27(1):16-9.

Indiziert‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (öffnet neues Fenster)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (öffnet neues Fenster)

Vidarsson B, Önundarson PT.

Quelle‎: Thromb Haemost 2000;83(4):634-5.

Indiziert‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (öffnet neues Fenster)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (öffnet neues Fenster)

Zver S, Andoljšek D, Černelč P.

Quelle‎: Eur J Haematol 2004;72(6):455-6.

Indiziert‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (öffnet neues Fenster)

Management of bleeding complications of hematologic malignancies. (öffnet neues Fenster)

Green D.

Quelle‎: Semin Thromb Hemost 2007;33(4):427-34.

Indiziert‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (öffnet neues Fenster)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (öffnet neues Fenster)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Quelle‎: Int J Lab Hematol 2013;35(4):457-9.

Indiziert‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (öffnet neues Fenster)

Management of bleeding in patients with advanced cancer. (öffnet neues Fenster)

Pereira J, Phan T.

Quelle‎: Oncologist 2004;9(5):561-70.

Indiziert‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (öffnet neues Fenster)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (öffnet neues Fenster)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Quelle‎: Haematologica 1997;82(5):584-7.

Indiziert‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (öffnet neues Fenster)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (öffnet neues Fenster)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Quelle‎: Bull Cancer 2006;93(2):E7-12.

Indiziert‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (öffnet neues Fenster)